Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2016-005251-25
    Sponsor's Protocol Code Number:CABACARE
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2021-10-01
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2016-005251-25
    A.3Full title of the trial
    CABAzitaxel with or without prednisone in patients with metastatic CAstration REsistant prostate cancer (mCRPC) progressed during or after a previous docetaxel-based chemotherapy: a multi-center, prospective, two-arm, open label, non inferiority phase II study.
    CABAzitaxel with or without prednisone in patients with metastatic CAstration REsistant prostate cancer (mCRPC) progressed during or after a previous docetaxel-based chemotherapy: a multi-center, prospective, two-arm, open label, non inferiority phase II study.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    CABAzitaxel with or without prednisone in patients with metastatic CAstration REsistant prostate cancer (mCRPC) progressed during or after a previous docetaxel-based chemotherapy: a multi-center, prospective, two-arm, open label, non inferiority phase II study.
    CABAzitaxel con o senza prednisone in pazienti affetti da carcinoma prostatico metastatico Castrazione-REsistente (mCRPC); in progressione durante o dopo il trattamento chemioterapico a base di docetaxel: uno studio di fase II di non inferiorità, multicentrico, prospettico, due bracci, in aperto.
    A.3.2Name or abbreviated title of the trial where available
    CABACARE
    CABACARE
    A.4.1Sponsor's protocol code numberCABACARE
    A.5.4Other Identifiers
    Name:CABACARENumber:CABACARE
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorCONSORZIO ONCOTECH
    B.1.3.4CountryItaly
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportSANOFI-AVENTIS
    B.4.2CountryItaly
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationCarlo Buonerba
    B.5.2Functional name of contact pointMedical monitoring
    B.5.3 Address:
    B.5.3.1Street AddressVia Pansini, 5
    B.5.3.2Town/ cityNapoli
    B.5.3.3Post code80131
    B.5.3.4CountryItaly
    B.5.4Telephone number081 7463662
    B.5.5Fax number081 7463662
    B.5.6E-mailcabacare@oncotech.org
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name JEVTANA - 60MG-CONCENT. E SOLV.PER SOLUZ. PER INFUSIONE-USO ENDOVENOSO -CONCENT.:FLACONC.(VETRO)SOLV.: FLACONC.(VETRO)-CONCENT.:1.5ML SOLV.:4.5ML-1FLAC.+1FLAC.
    D.2.1.1.2Name of the Marketing Authorisation holderSANOFI-AVENTIS GROUPE
    D.2.1.2Country which granted the Marketing AuthorisationItaly
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNCABAZITAXEL
    D.3.9.1CAS number 183133-96-2
    D.3.9.2Current sponsor codeNA
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number40
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name DELTACORTENE - 5 MG COMPRESSE10 COMPRESSE
    D.2.1.1.2Name of the Marketing Authorisation holderBRUNO FARMACEUTICI S.P.A.
    D.2.1.2Country which granted the Marketing AuthorisationItaly
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNPREDNISONE
    D.3.9.1CAS number 53-03-2
    D.3.9.2Current sponsor codeNA
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Metastatic Castration Resistant Prostate Cancer (mCRPC) progressed during or after a previous docetaxel-based chemotherapy.
    Pazienti affetti da carcinoma prostatico metastatico Castrazione-REsistente (mCRPC); ); in progressione durante o dopo il trattamento chemioterapico a base di docetaxel”.
    E.1.1.1Medical condition in easily understood language
    Metastatic Castration Resistant Prostate Cancer (mCRPC)
    Carcinoma prostatico con metastasi, resistente alla castrazione.
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.1
    E.1.2Level PT
    E.1.2Classification code 10062904
    E.1.2Term Hormone-refractory prostate cancer
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.1
    E.1.2Level PT
    E.1.2Classification code 10036909
    E.1.2Term Prostate cancer metastatic
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate whether cabazitaxel alone is non inferior in terms of radiographic PFS with respect to cabazitaxel plus daily prednisone in patients with castration resistant prostate cancer.
    Valutare in termini di PFS radiografica se il cabazitaxel da solo non risulta essere inferiore rispetto al cabazitaxel somministrato con l’aggiunta di una dose giornaliera di prednisone, in pazienti affetti da carcinoma prostatico castrazione-resistente.
    affetti da carcinoma prostatico resistente alla castrazione.
    E.2.2Secondary objectives of the trial
    • Safety in the two treatment arms;
    • Health-Related Quality of Life (HRQL) and pain;
    • Objective Response Rate (ORR) according to Response Evaluation Criteria In Solid Tumors (RECIST 1.1);
    • Biochemical response (assessed considering PSA decrease =50% and waterfall plot results);
    • Time to PSA Progression (TTPP);
    • Radiographic Time to Progression (rTTP);
    • Overall Survival (OS);
    • Association of Overal Survival (OS), Progression Free Survival (PFS) and Objective Response Rate (ORR) with AR-V7 and RB status in circulating tumor cells assessed at flow-cytometry;
    • Time to Skeletal-Related Event (SRE);
    • Sicurezza nei due bracci di trattamento;
    • Qualità della vita correlato allo stato di salute (HRQL) e percezione del dolore;
    • Tasso di risposta obiettiva (ORR) secondo i criteri di valutazione delle risposte nei tumori solidi (RECIST 1.1);
    • Risposta biochimica (valutata considerando una diminuzione di PSA =50% e i risultati dai grafici waterfall);
    • Tempo di progressione di PSA (TTPP);
    • Tempo di progressione radiografica (rTTP);
    • Sopravvivenza globale (OS);
    • Associazione tra la sopravvivenza globale (OS), sopravvivenza libera da progressione (PFS) e tasso di risposta obiettiva (ORR) con analisi dello stato mutazionale di ARV-7 e RB nelle cellule tumorali circolanti, valutati mediante citofluorimetria.
    • Tempo di manifestazione di eventi scheletrici correlati (SRE);
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Signed informed consent.
    2. Histological diagnosis of prostate adenocarcinoma;
    3. Metastatic castration-resistant disease with documented radiographic progression (osseous or measurable lesions) during or after a docetaxel-based chemotherapy;
    4. Testosterone level in the castration range (levels <50 ng/dl) because of a previous, and ongoing, androgen deprivation with LH-RH agonists or antagonists or bilateral orchiectomy;
    5. Prior surgery and/or radiation therapy (to less or equal than 30% of the bone marrow) are allowed. However, at least 4 weeks must have been elapsed since surgery or completion of radiation therapy and the patient must has recovered from side effects;
    6. Life expectancy = 3 months;
    7. Age > 18 years;
    8. ECOG performance status 0-2;
    9. ANC = 1.5 x 109/L;
    10. PLT = 100 x 109/L;
    11. Hb = 10 g/dl;
    12. Serum total bilirubin = UNL;
    13. AST/SGOT and/or ALT/SGPT =1,5 x ULN;
    14. Serum Creatinine =1,5 times UNL (in case of limit values of serum creatinine, creatinine clearance calculated by CKD-EPI formula should be =60 ml/min);
    15. PT or INR and PTT <1,5 times UNL (Note: patients who receive anti-coagulation treatment will be allowed to participate provided that any abnormality in these parameters exists);
    16. Patients must be accessible for treatment and follow up;
    1. Firma del consenso informato.
    2. Diagnosi istologica di adenocarcinoma prostatico;
    3. Malattia metastatica resistente alla castrazione in progressione radiografica documentata (lesioni ossee o misurabili) in seguito o durante un precedente trattamento chemioterapico a base di docetaxel;
    4. Livelli di testosterone compresi nei range di castrazione (livello <50 ng/dl) a causa di una precedente e attuale terapia di deprivazione androgenica con agonisti o antagonisti LH-RH o, orchiectomia bilaterale ;
    5. Sono ammessi pazienti che hanno subito chirurgia preventiva e / o radioterapia (a meno del o pari al 30% del midollo osseo). Tuttavia, devono essere trascorse almeno 4 settimane dall’intervento chirurgico o dal completamento della radioterapia ed inoltre il paziente deve essersi ripreso dagli eventuali effetti collaterali;
    6. Aspettativa di vita = 3 mesi;
    7. Età > 18 anni;
    8. ECOG performance status 0-2;
    9. ANC = 1.5 x 109/L;
    10. PLT = 100 x 109/L;
    11. Hb = 10 g/dl;
    12. Bilirubina sierica totale = UNL;
    13. AST/SGOT e/o ALT/SGPT = 1,5 x ULN;
    14. Creatinina sierica =1,5 times UNL (in caso di valori limite di creatinina sierica, la clearance della creatinina calcolata con la formula CKD-EPI dovrà essere = 60 ml/min);
    15. PT o INR e PTT < 1,5 volte UNL (Nota: i pazienti che ricevono un trattamento anticoagulante potranno partecipare a condizione che non esista alcuna anomalia in questi parametri);
    16. I pazienti devono essere partecipi al trattamento ed al follow up;
    E.4Principal exclusion criteria
    1. Participation in clinical trials with other investigational drug within 28 days of study entry;
    2. Symptomatic or uncontrolled brain metastases. Patients with neurological symptoms must undergo a computed tomography (CT) scan/magnetic resonance imaging (MRI) of the brain to exclude brain metastasis; previously treated brain metastases will be allowed as long as the patient is neurologically stable and does not require steroids and anticonvulsants;
    3. Less than 4 weeks elapsed from prior anticancer-therapy or surgery to the time of randomization. Patient may be on bisphosphonates prior to study entry. Prior treatment with abiraterone or enzalutamide is allowed and is used as a stratification factor at randomization. Patient may be on biphosphonates prior to study entry;
    4. Less than 4 weeks from palliative Radiotherapy to time of randomization;
    5. Any of the following within 6 months prior to study enrollment: myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, NYHA class III or IV congestive heart failure, stroke or transient ischemic attack, pulmonary embolism or other uncontrolled thromboembolic event;
    6. Any severe acute or chronic medical condition which could impair the ability of the patient to participate to the study or interfere with interpretation of study results, or patient unable to comply with the study procedures;
    7. Unstable diabetes mellitus, resistant peptic ulcer disease, erosive esophagitis or gastritis, infectious or inflammatory bowel disease, acute diverticulitis or other contraindications to use of corticosteroid treatment;
    8. Peripheral neuropathy Grade > 2 (National Cancer Institute Common Terminology Criteria (NCI CTCAE v.4.03);
    9. Previous beta or gamma Isotope treatment (e.g. strontium or samarium), alpha emitters are allowed;
    10. History of severe hypersensitivity reaction (> grade 2) to polysorbate 80 containing drugs;
    11. Concurrent or planned treatment with strong inhibitors or strong inducers of cytochrome P450 3A4/5 (a 2-week washout period is necessary for patients who are already on these treatments);
    12. Previous malignancy except for basal cell or squamous cell skin cancer adequately treated, or any other cancer from which the patient has been disease-free for = 5 years;
    13. Patients with reproductive potential who do not agree to use accepted and effective method of contraception, based on the investigator’s judgment, during the study treatment period.
    1.La partecipazione in studi con altri farmaci sperimentali entro 28 giorni dall’ingresso nello studio;
    2.Presenza di metastasi cerebrali sintomatiche o non controllate. I pazienti con sintomi neurologici devono essere sottoposti a una tomografia computerizzata (CT), ad un imaging a risonanza magnetica (MRI) del cervello per escludere metastasi cerebrali; i pazienti che hanno avuto metastasi cerebrali trattate in precedenza potranno accedere fintanto che il paziente risulti essere neurologicamente stabile senza richiedere una terapia con steroidi e anticonvulsivanti;
    3.Se al giorno della randomizzazione sono trascorse meno di 4 settimane dalla prima terapia antitumorale o dall’intervento chirurgico. Il paziente può essere stato sottoposto ad un trattamento con bifosfonati prima dell’ingreso nello studio.
    E’ permesso un precedente trattamento con abiraterone o enzalutamide , verrà utilizzato come fattore di stratificazione al momento della randomizzazione. I pazienti possono essere in trattamento con bifosfonati nel periodo precedente l’ingresso nello studio;
    4. Se al giorno della randomizzazione sono trascorse meno di 4 settimane da radioterapia palliative;
    5.Se si verifica una delle seguenti condizioni, 6 mesi prima dell’arruolamento nello studio: infarto del miocardio, angina pectoris severa/instabile, impianto di bypass arterioso/coronarico, insufficienza cardiaca congestizia di classeNYHA III o IV, ictus o attacco ischemico transitorio, embolia polmonare o altro evento tromboembolico incontrollato;
    6.Qualsiasi grave condizione medica acuta o cronica che potrebbe compromettere la capacità del paziente di partecipare allo studio o interferire con l'interpretazione dei risultati dello studio, o pazienti non capaci di rispettare le procedure dello studio;
    7.Diabete mellito instabile, ulcera peptica resistente, esofagite erosiva o gastrite, malattie intestinali infiammatorie o infettive, diverticolite acuta o altre controindicazioni all’uso di trattamento con corticosteroidi;
    8.Neuropatia periferica di grado > 2 (criteri del National Cancer Institute - NCI CTCAE v.4.03);
    9.Precedente trattamento con isotopi beta o gamma (ad esempio, stronzio o samario), gli emettitori alfa sono consentiti;
    10. Storia di gravi reazioni di ipersensibilità (> grado 2) al polisorbato 80, contenuto nei farmaci;
    11.Il trattamento concomitante o programmato con potenti inibitori o potenti induttori del citocromo P450 3A4/5 (è necessario un periodo di washout di 2 settimane per i pazienti che sono già stati trattati);
    12.Neoplasia precedente tranne che per tumore baso-cellulare o cancro della pelle a cellule squamose adeguatamente trattato, o qualsiasi altro cancro da cui il paziente è stato libero da malattia per un tempo = 5 anni;
    13.I pazienti potenzialmente fertili che durante il periodo di trattamento dello studio non acconsentono ad utilizzare un metodo accettato ed efficace di contraccezione, secondo il giudizio dello sperimentatore.
    E.5 End points
    E.5.1Primary end point(s)
    Radiographic Progression-Free Survival (rPFS)
    Sopravvivenza libera da progressione radiografica (rPFS)
    E.5.1.1Timepoint(s) of evaluation of this end point
    Screening, and then every 9 weeks for the first 18 weeks, then every 12 weeks, until radiographic tumor progression is documented or study cut-off.
    Screening, e poi ogni 9 settimane per le prime 18 settimane, poi ogni 12 settimane, fino alla progressione tumorale radiografica documentata o cut-off dello studio.
    E.5.2Secondary end point(s)
    Safety in the two treatment arms;; Health-Related Quality of Life HRQL and pain;
    Objective Response Rate (ORR) according to Response Evaluation Criteria In Solid Tumors (RECIST 1.1).; Biochemical response (PSA decrease =50%); Overall Survival (OS); AR-V7 and RB status in circulating tumor cells by the use of Adna test.; Time to Skeletal-Related Event (SRE).
    sicurezza nei due bracci di trattamento; •qualità della vita, stato di salute generale (HRQL) e percezione del dolore; risposta obiettiva (ORR) secondo i criteri di valutazione delle risposte nei tumori solidi (RECIST 1.1)
    ; Risposta biochimica (diminuzione di PSA =50%); Sopravvivenza globale (OS); Analisi dello stato mutazionale di ARV-7 e RB nelle cellule tumorali circolanti.; Tempo di manifestazione di eventi scheletrici correlati (SRE).
    E.5.2.1Timepoint(s) of evaluation of this end point
    every 4 weeks; They will be evaluated at Screening and every 4 weeks of treatment.; Results must be available prior to each cycle of treatment; Defined as the time interval from the date of randomization to the date of death due to any cause. ; The test will be performed at baseline; every 4 weeks.
    ogni 4 settimane ; Saranno valutati allo Screening ed ogni 4 settimane di trattamento.; I risultati devono essere disponibili prima di ogni ciclo di trattamento.; Definito come l'intervallo di tempo a partire dalla data di randomizzazione alla data di morte per qualsiasi causa.; Il test sarà effettuato al baseline; ogni 4 settimane.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other Yes
    E.8.2.3.1Comparator description
    Stesso farmaco in combinazione con prednisone
    The same drug in combination with prednisone
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned22
    E.8.5The trial involves multiple Member States No
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS until death or the study cut-off.
    LVLS fino a decesso o cut-off.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years4
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years4
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 66
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 154
    F.2 Gender
    F.2.1Female No
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations No
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state220
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 220
    F.4.2.2In the whole clinical trial 220
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Each patient will be treated until radiological disease progression, unacceptable toxicity, or patient refusal. Patients will be followed through subsequent therapy lines of treatments until death or the study cut-off, whichever comes first.
    Ciascun paziente sarà trattato fino a progressione radiologica della malattia, tossicità inaccettabile o rifiuto del paziente. I pazienti saranno seguiti relativamente alle successive linee terapiche di trattamento fino al decesso al cut off dello studio o qualsiasi di esso si verifichi prima.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2017-04-07
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2017-02-22
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 15:35:28 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA